Shows
Tech on Drugs with Shai Shen-OrrTOD - 2025_04_17 - Nir HacohenWe’re kicking off Season 3 of Tech on Drugs with Prof. Nir Hacohen — Director of the Center for Cancer Research at MGH, founding director of the Broad Institute’s Cell Circuits Program, and a distinguished member of CytoReason's Science Advisory Board.Shai and Nir cover everything from the rise of antibodies and the promise (and pitfalls) of STING agonists, to the future of personalized cancer vaccines and a mysterious immune cell that appears only in patients with sepsis — a “cell that doesn’t exist” in healthy individuals.This is a candid, fascinating look at how deep biology, smart...2025-05-111h 01
Empowered Patient PodcastComputational AI Bringing Predictability Precision to Drug Discovery and Clinical Trials with Shai Shen-Orr CytoReason TRANSCRIPT Shai Shen-Orr, the Co-Founder and Chief Scientist of CytoReason, is developing computational disease models powered by AI to improve the probability of success in phase 2 clinical trials. Their goal is to more precisely develop drugs using AI to analyze large amounts of biological and clinical data and overcome the challenges of the complexity and uncertainty in medical information. Working with large pharmaceutical companies, CytoReason is supporting companies in their drug development efforts and helping them choose the right drug target and patient populations to study. Shai explains, "There are many challenges. I would say that CytoReason right n...2024-11-2100 minEmpowered Patient PodcastComputational AI Bringing Predictability Precision to Drug Discovery and Clinical Trials with Shai Shen-Orr CytoReason Shai Shen-Orr, the Co-Founder and Chief Scientist of CytoReason, is developing computational disease models powered by AI to improve the probability of success in phase 2 clinical trials. Their goal is to more precisely develop drugs using AI to analyze large amounts of biological and clinical data and overcome the challenges of the complexity and uncertainty in medical information. Working with large pharmaceutical companies, CytoReason is supporting companies in their drug development efforts and helping them choose the right drug target and patient populations to study. Shai explains, "There are many challenges. I would say that CytoReason right n...2024-11-2121 min
Tech on Drugs with Shai Shen-OrrTech On Drugs - Se2Ep4 - Dr. Tom BumolTom Bumol's career spans major roles at Eli Lilly, the Allen Institute, and beyond. He is also a distinguished member of CytoReason's Science Advisory Board.In this episode, Tom shares insights into drug development's successes, failures, and future direction, including:Lessons from lupus - the story of a failed lupus trial that revealed the critical importance of understanding disease heterogeneity and inspired new approaches in immunology.From trial and error to predictability - how AI and systems biology can transform drug development by embracing human complexity.Combination therapies and beyond - designing drugs wit...2024-11-2143 min
BiotalkBiotalk Episode 20: A Conversation with David Harel of CytoReasonOn this episode of BioTalk, Geoff Meyerson, CEO of Locust Walk, sits down with David Harel, CEO and Co-founder of CytoReason. CytoReason uses AI-powered disease models to transform drug discovery and development, offering pharmaceutical companies insights that reduce both time and costs in bringing new therapies to market.David shares his journey from private equity to co-founding CytoReason—an idea sparked on a beach in Israel. They discuss why no one had applied molecular data this way before, how CytoReason’s models differ from existing approaches, and the benefits they offer in accelerating drug deve...2024-11-1834 min
Tech on Drugs with Shai Shen-OrrTech On Drugs - Se2Ep3 - Dr. Yair BenitaThis episode was recorded in the beautiful Island of Crete, at CytoReason's employee conference, the CytoSummit.CytoReason's Co-founder Shai Shen-Orr hosts AION Labs CTO Yair Benita. Yair is a computational biologist who spent more than 20 years studying biology through omics and clinical data in an effort to piece together mechanisms of human disease. He’s been leading computational teams in drug discovery at CytoReason, Compugen, and Merck. In this candid conversation with Shai, Yair reflects on the highs and lows of his professional journey over the past two decades, as well as the broader indus...2024-10-1430 min
AI News DailyOpenAI and Microsoft launch GPT-4o, NeRF Inpainting Revolutionizes Visual Creation, Mistral AI unveils Mistral NeMo, CytoReason Raises $130M, and more...(0:10): OpenAI and Microsoft Launch GPT-4o Mini: Affordable AI Model Dominates Competitors(2:11): New Generative NeRF Inpainting Technique Revolutionizes 3D and 4D Visual Content Creation(4:41): Mistral AI and NVIDIA Unveil Mistral NeMo: A 12-Billion-Parameter Game-Changer for Enterprises(6:28): Israeli Biotech CytoReason Raises $130M to Revolutionize AI-Driven Disease Modeling and Drug Development(8:57): Nvidia Launches R555 Series, Begins Shift to Open-Source GPU Drivers for Enhanced PerformanceTo subscribe visit https://www.brief.news.For more updates...2024-07-1911 min
Tech on Drugs with Shai Shen-OrrTech On Drugs - Se2Ep2 - Prof. Asya RollsWhile most neuroimmunologists try to understand how the immune system affects the brain, Prof. Asya Rolls has taken the road less traveled in her lab at the Technion. She and her team try to understand how the brain affects the immune system. In this episode of Tech on Drugs, Asya and Shai talked about the power of placebo and how brain activity, particularly in the reward system, can influence the immune system. They discussed the immense potential of harnessing brain-immune pathways for new treatment approaches. For example, research that shows that stimulating certain brain areas can bo...2024-06-2023 min
ניהול בשיטת אימStartUp Downפרק 44: עקרונות מנחים לניהול כספים מוצלח בסטארטאפ. "הקול שלך" אופק לוי מחברת CytoReasonפרק 44: עקרונות מנחים לניהול כספים מוצלח בסטארטאפ. "הקול שלך" אופק לוי מחברת סייטו-ריזן
"Your Voice Episode": Ofek Levy, CFO CytoReason: CFO management Insights
בפרק הזה רצינו לראות: "איך הדברים נראים כשמביטים במספרים?"
את הפרק התחלנו עם היכרות קצרה עם אופק והמסלול שעשה עד לתפקידו הנוכחי כסמנכ"ל הכספים של חברת סטארטאפ מיוחדת. המשכנו בשיחה על המתח שבין "שומר הסף" לבין גורם מאפשר. השבנו על השאלות הבאות:
מה ניתן ללמוד מהמספרים וכיצד מנהלים בכל הדרגים ולא רק מנכ"ל ומנהלים בכירים, יכולים להיעזר בנתונים האלה כדי לטייב ולנתב את אנשיהם וביצועיהם?
על בעלי העניין השונים שמושכים כל אחד לתחום אחריותו ואת מי באמת משרת ה-CFO?
איך אפשר ונכון להתמודד עם פערי ידע או ביטחון בתפקידים שדורשים מאתנו קבלת החלטות גם ללא ניסיון רלוונטי?
#FinanceManagement #CFOManagementInsigths #YourVoice #VBM #CytoReason
2024-03-3129 min
Tech on Drugs with Shai Shen-OrrTech On Drugs - Se2Ep1 - Prof. Eran SegalThis one was fun.In the latest episode of Tech on Drugs, Shai met with Prof. Eran Segal from the Weizmann Institute of Science.Eran heads a multidisciplinary team of computational biologists and experimental scientists working in the area of Computational and Systems biology. His lab at Weizmann aims to develop personalized nutrition and personalized medicine using machine learning, computational biology, probabilistic modeling, and analysis of heterogeneous high-throughput genomic and clinical data.Among other things, Eran and Shai talked about precision nutrition and preventative medicine, and the importance of large-scale, longitudinal health data for...2024-03-2125 min
Michael Gale's Futures In FocusShai Shen-Orr and David Harel - Precision Medicine Will Transform The Patient ExperienceProfessor Shai Shen-Orr and David Harel of Cytoreason talk about the future of precision medicine. The idea of being able to go to your personal doctor and asking how your immune system is doing seems like science fiction, but is likely to be a reality soon. Hear from two leading experts using AI and cell-based research to reveal the future of medicine.2024-02-1934 min
Tech on Drugs with Shai Shen-OrrTech On Drugs - Episode 5 - Prof. Ido AmitOur guest this time was Prof. Ido Amit, whose lab at the Weizmann Institute of Science pioneered single cell transcriptomic analysis and its application to the immune system.Amit’s research focuses on some of the most important questions in immunology – specifically those relevant to novel targets for immunotherapy in autoimmune diseases, neurodegeneration, and cancer.A fascinating discussion between two leading scientists about the potential of single cell RNA analysis to revolutionize target discovery and drug development.2023-09-2828 min
Disruptive CEO NationEpisode 196: David Harel, Co-Founder and CEO of CytoReason, IsraelCytoReason is supporting some of the largest pharma companies and research institutes with their boldest attempts to improve people lives through improved clinical design and speeding the discovery of new life-saving drugs. Using the knowledge the world has accumulated to intelligently augment clients’ data and to identify patterns within it and generate a system-level understanding of immunity. These patterns then become powerful tools for explaining, predicting and optimizing outcomes proving guidance in both drug discovery and clinical trials.I spoke with David from his office in TelAviv and here is some of wh...2023-05-1026 min
Tech on Drugs with Shai Shen-OrrTech On Drugs - Episode 4 - Dr. Emanuele de Rinaldis, SanofiWhat will the future of precision medicine look like 5-10 years down the line? And how will AI accelerate this future?I asked Dr. Emanuele de Rinaldis to answer this and many other questions. Emanuele is VP, Global Head of Precision Medicine & Computational Biology at Sanofi R&D. He believes that AI will help us define new taxonomies of diseases. We will identify different types of Asthma, different types of Fibrosis.And AI will help us create a new textbook – not one driven by just clinical observations, but a textbook driven by ge...2023-04-2826 min
Tech on Drugs with Shai Shen-OrrTech On Drugs - Episode 3 - Prof. Yanay OfranOur guest this time is serial biotech entrepreneur Yanay Ofran. Yanay is a renowned computational biophysicist and the CEO and Co-founder of Biolojic Design. More importantly, Yanay, together with his stellar team, developed the first AI-designed antibody. He shared with Shai his (strong) opinions about: The barriers to precision medicine (and how to overcome them).The potential of AI-designed antibodies (and how, just a few weeks ago, a cancer patient in North Carolina became the first American to receive treatment with such an antibody).The reasons why even in this golden digital era drug development is still insanely expensive...2023-03-1634 min
Tech on Drugs with Shai Shen-OrrTech on Drugs - Episode 2 - Prof Yehuda ChowersThe doctor in the clinic must build on molecular features and the bioinformatician in the lab must build on data from the clinic. Prof. Yehuda Chowers, a leading gastroenterologist, has been harping on this point for years. It's a two-way street that will benefit both drug makers and drug consumers. In this episode of TOD, Chowers talks to host Shai Shen-Orr about immunogenicity, clinical trials, and population models.2023-02-1327 min
Tech on Drugs with Shai Shen-OrrTech on Drugs - Episode 1 - Ran BalicerOur first episode features world renowned epidemiologist, Prof. Ran Balicer, Chief Innovation Officer at Clalit Health Services, Israel’s largest healthcare organization. We talked about the mining of real-world data and how it guides healthcare policy. The impact on Covid is pretty mind-boggling!2023-01-1628 min
Tech on Drugs with Shai Shen-OrrIntroducing - Tech on DrugsThis is a podcast about the future of pharma. From novel targets to novel biomarkers. From disease models to population models. From clinical trials to synthetic trials. In each episode, our host Prof. Shai Shen-Orr talks to world-leading scientists and healthcare executives about the future of pharma.2023-01-1200 min
Empowered Patient PodcastUsing Computational Disease Models and Synthetic Clinical Trials for Drug Research and Development with David Harel CytoReason TRANSCRIPTDavid Harel is the Co-Founder and CEO of CytoReason, providing researchers and drug developers with a complex database and predictive computational disease models to conduct synthetic clinical trials. Their mission is to integrate all the information available on a specific disease in a particular population to support faster and more efficient drug development. David explains, "Computational disease models are the core technology that we've developed, and it is a method to incorporate all the available information, specifically omics and molecular data, that is available in one disease, in one place, in a way that is useful. But...2023-01-0900 minEmpowered Patient PodcastUsing Computational Disease Models and Synthetic Clinical Trials for Drug Research and Development with David Harel CytoReasonDavid Harel is the Co-Founder and CEO of CytoReason, providing researchers and drug developers with a complex database and predictive computational disease models to conduct synthetic clinical trials. Their mission is to integrate all the information available on a specific disease in a particular population to support faster and more efficient drug development. David explains, "Computational disease models are the core technology that we've developed, and it is a method to incorporate all the available information, specifically omics and molecular data, that is available in one disease, in one place, in a way that is useful. But...2023-01-0920 min
Radio and Social Media News ChannelEp 4: CytoReason: Making medicine more efficientIn this episode, Jonny heads to the Startup Nation to investigate a company who are making the impossible in medicine possible.
Through artificial intelligence and machine learning, CytoReason are working with Big Pharma to find new targets to fight disease and improve drug development.
They produce huge amounts of data, building disease models with it, so drawing parallels between what seemed unrelated diseases which doctors weren't able to see before.
This is a remarkable story which offers human advancement to the world.
#JonnyWalks is proudly sponsored by BOOST&Co.2020-03-0335 minRadio and Social Media News ChannelEp 3 Part 2: Furniture refreshing and medical miraclesHere's the mini-cast, part 2 of each month's record of Jonny's travels through the corridors of SMEs who are disrupting the big players and innovating with new processes and products.
We return to "Furniture Central" in London's Tottenham Court Road for a shorter version of Jonny's interview with Keiran Hewkin, Lombok's Commercial Director, who with his partner, Paul Fielden have deconstructed then reconstructed "the way we think about buying furniture".
Scroll back for the full interview with Keiran, Episode 3. It's really good!
Then it's off to the Startup Nation, Israel, for an introduction to CytoReason, who use AI and Machine Learning...2020-02-1810 min
Artificial Intelligence in Drug DiscoveryShai Shen-Orr, Chief Scientist, CytoReason, AI in ImmunologyOn this episode, I speak with Shai Shen-Orr, cofounder and chief scientist of CytoReason ( www.cytoreason.com ). CytoReason has created a machine learning model of the immune system. This model can integrate data from multiple sources to support drug discovery, the creation of diagnostic tools, and more. In this episode, you’ll learn about systems immunology, its potential in medicine, and how CytoReason applies artificial intelligence to make sense of the growing body of immune-related data.
This episode is brought to you by BenchSci ( www.benchsci.com ). BenchSci uses artificial intelligence to reduce the cost of scientific experiments. Use it to...2018-06-2031 min